Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05883644 · ClinicalTrials.gov registry record · Phase 3
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
A Phase 3 study of Advanced Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 111
- Enrollment target
- 20
- Study locations
NCT05883644 is a Phase 3 study of Advanced Hepatocellular Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 111 participants, above the 81-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05883644, a Phase 3 study of Advanced Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 111 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
Study Locations (20)
Other
- Research Site - Bobigny
- Research Site - Clichy
- Research Site - Créteil
- Research Site - Marseille
- Research Site - Rennes
- Research Site - Berlin
- Research Site - Cologne
- Research Site - Frankfurt
- Research Site - Lübeck
- Research Site - Hong Kong
- Research Site - Shatin
- Research Site - Milan
- Research Site - Naples
- Research Site - Padua
- Research Site - Pisa
- Research Site - Rozzano
- Research Site - Turin
California
- Research Site - La Jolla
Louisiana
- Research Site - Shreveport
Michigan
- Research Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05883644
The ClinicalTrials.gov registry entry for NCT05883644 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (37% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT05883644 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05883644 about?
NCT05883644 is a clinical study titled "Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)". This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
What is the current status of trial NCT05883644?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 111 participants. The study started on 2023-06-27. Estimated completion is 2026-09-30.
What conditions does trial NCT05883644 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05883644?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT05883644?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05883644 being conducted?
This trial has 20 study locations across California, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RECRUITING · Phase 3
-
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RECRUITING · Phase 1
-
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
RECRUITING · Phase 2
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Ligufalimab and Cadonilimab in Advanced Liver Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.